These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 12426631

  • 41. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
    Kolnagou A, Kontoghiorghes GJ.
    Br J Haematol; 2010 Aug; 150(4):489-90; author reply 491. PubMed ID: 20507309
    [No Abstract] [Full Text] [Related]

  • 42. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 43. Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.
    Janka GE, Möhring P, Helmig M, Haas RJ, Betke K.
    Eur J Pediatr; 1981 Nov; 137(3):285-90. PubMed ID: 7318841
    [Abstract] [Full Text] [Related]

  • 44. Current status of iron chelation therapy with deferoxamine.
    Cohen A.
    Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
    [Abstract] [Full Text] [Related]

  • 45. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload.
    Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G.
    Blood; 2000 May 01; 95(9):2776-9. PubMed ID: 10779420
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.
    Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S.
    Blood; 1996 Jul 15; 88(2):705-13. PubMed ID: 8695819
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
    Olivieri NF, Koren G, St Louis P, Freedman MH, McClelland RA, Templeton DM.
    Semin Hematol; 1990 Apr 15; 27(2):101-4. PubMed ID: 2190316
    [No Abstract] [Full Text] [Related]

  • 51. Combined iron chelation therapy.
    Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW.
    Ann N Y Acad Sci; 2010 Aug 15; 1202():79-86. PubMed ID: 20712777
    [Abstract] [Full Text] [Related]

  • 52. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun 15; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

  • 53. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr 15; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 54. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M.
    Hemoglobin; 2014 Apr 15; 38(2):111-4. PubMed ID: 24351163
    [Abstract] [Full Text] [Related]

  • 55. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B.
    Transfusion; 2013 Aug 15; 53(8):1722-9. PubMed ID: 23241074
    [Abstract] [Full Text] [Related]

  • 56. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb 15; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 57. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Feb 15; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 58. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
    Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G.
    Br J Haematol; 2006 Aug 15; 134(4):438-44. PubMed ID: 16822284
    [Abstract] [Full Text] [Related]

  • 59. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar 15; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 60. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V, Kurtoglu E.
    Hematology; 2013 Jan 15; 18(1):50-5. PubMed ID: 23321010
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.